Dr. Vivek Subbiah, MD
Medical Oncology (Medical Oncology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 4
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 67
Licensed in California since 2026, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 347514 · CA license C206969 (first issued 2026; current) -
Hematology & Oncology Physician
TX license N6693 -
Internal Medicine Physician
CA license C206969 (first issued 2026; current) · TX license N6693 -
Pediatric Hematology & Oncology Physician
CA license C206969 (first issued 2026; current) · TX license N6693 -
Pediatrics Physician
TX license N6693
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
- Verdi Oncology Tennessee PC (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 67
- Services billed
- 9,527
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 183 | 83 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 22 companies reported 74 payments worth $48,973 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $20,633 |
|---|---|
| Pfizer Inc. | $6,148 |
| AstraZeneca Pharmaceuticals LP | $5,947 |
| Rigel Pharmaceuticals, Inc. | $3,517 |
| AbbVie Inc. | $2,968 |
| Incyte Corporation | $2,859 |
| Novartis Pharma AG | $2,700 |
| AstraZeneca UK Limited | $2,050 |
| Consulting Fee | $36,910 |
|---|---|
| Travel and Lodging | $6,583 |
| Honoraria | $3,425 |
| Food and Beverage | $2,055 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Consulting Fee | $12,889 |
| E.r. Squibb & Sons, L.l.c. Mar 21, 2025 | Travel and Lodging travel to Paris, France | $5,427 |
| Rigel Pharmaceuticals, Inc. Jun 12, 2025 | Honoraria GAVRETO · Oncology | $3,425 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Consulting Fee | $3,280 |
| AbbVie Inc. Mar 13, 2025 | Consulting Fee | $2,900 |
| Incyte Corporation Jun 6, 2025 | Consulting Fee | $2,842 |
| Novartis Pharma AG Jan 28, 2025 | Consulting Fee MEKINIST · Oncology | $2,700 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting Fee DATROWAY · Oncology | $2,460 |
| Pfizer Inc. Nov 5, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $2,160 |
| AstraZeneca UK Limited Jun 23, 2025 | Consulting Fee ENHERTU · Oncology | $2,050 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 5, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $2,160 |
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Consulting Fee | $12,889 |
| Pfizer Inc. Sep 25, 2025 | Consulting Fee | $1,950 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 17, 2025 | Consulting Fee | $686 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 17, 2025 | Consulting Fee | $686 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $324 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| Pfizer Inc. Jul 9, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $1,800 |
| AstraZeneca UK Limited Jun 23, 2025 | Consulting Fee ENHERTU · Oncology | $2,050 |
| Rigel Pharmaceuticals, Inc. Jun 12, 2025 | Honoraria GAVRETO · Oncology | $3,425 |
| Incyte Corporation Jun 6, 2025 | Consulting Fee | $2,842 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Consulting Fee | $3,280 |
| E.r. Squibb & Sons, L.l.c. Apr 21, 2025 | Consulting Fee | $508 |
| E.r. Squibb & Sons, L.l.c. Mar 21, 2025 | Travel and Lodging travel to Paris, France | $5,427 |
| AbbVie Inc. Mar 13, 2025 | Consulting Fee | $2,900 |
| Novartis Pharma AG Jan 28, 2025 | Consulting Fee MEKINIST · Oncology | $2,700 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting Fee DATROWAY · Oncology | $2,460 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 23 industry-funded studies in 2025, from 16 companies. The companies reported $2,015,319 in research payments for these studies, mostly to the institutions running them.
- A phase 1 clinical study to evaluate the safety, tolerability, pharmac
GlaxoSmithKline, LLC. - A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid Tumors
Genmab A/s - MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06586515 - The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Incyte Corporation - A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Beone Medicines Ltd. · Recruiting · NCT06427941 - A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06607185 - A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippe…
Merck Sharp & Dohme LLC - A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation - Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors
Exelixis Inc. - An openlabel phase 1 study to evaluate PF08046037 as monotherapy and part of combination therapy in participants with advanced malignancies
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.